 SOLANA BEACH, Calif., Jan. 20, 2021 GLOBE NEWSWIRE -- Evoke Pharma, Inc. Nasdaq: EVOK, a specialty pharmaceutical company focused on treatments for gastrointestinal GI disorders and diseases, announced today the completion of its follow-on offering of 5,750,000 shares of its common stock, including 750,000 shares of common stock sold pursuant to the underwriters full exercise of its option to purchase additional shares, at a price to the public of 2.50 per share. The gross proceeds from the offering were approximately 14.4 million, before underwriting discounts and commissions and estimated offering costs. 